Irvine, CA (PRWEB) February 25, 2013
EP Global Communications, Inc. (the Company), (Pink Sheets: EPGL.PK) is pleased to provide shareholders with the following major updates for the month of March 2013 and beyond:
First, the Company announces that up to 12 new medical device patents will be filed in the month of March, 2013. These patent filings will coincide with previously mentioned device technologies in research and development and additional new technologies which have not been publicly announced as yet. In addition, at least 3 new FDA 510k Applications will be put in process in March, 2013.
Second, the MPDD device will be released on March 25, 2013. Very positive reviews from Pain Physicians and inquiries from patients who are in pain and desperately seeking solutions, has prompted the Company to advance the timetable for MPDD. Shareholders can expect additional updates on this development as the time draws closer.
Third, the MPTT (Muscle Pain Trigger-Point Treatment) is being put on a track to be released by December, 2013 pending FDA 510k approval. The MPTT FDA 510k approval is expected by September, 2013. At least two other FDA 510k applications will be pending and the Company is optimistic those will be approved in the same approximate time frame. As the research and design phases of new devices is a fluid situation, more FDA 510 and PMA filings may be announced in the near future.
Fourth, DTC restrictions on some brokers are expected to be lifted at any moment. The Company counsel has filed all requisite documents and all brokers should have access to EPGL stock electronic deposit services, shortly.
Fifth, as shareholders know, the Company has achieved Current Information status with OTC Markets. Now, the Company plans to graduate the EPGL symbol to OTCQX by end of year 2013.
Following that movement, the next goal will be to bring the Company to NASDAQ or NYSE
Copyright©2012 Vocus, Inc.
All rights reserved